PharmaRadar360

PharmaRadar360

🇺🇸·Sep 2Regulatory

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Mifepristone and Analogues To Treat Hypercortisolism-Related Insulin Resistance Disorders

The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National I...

Publisher

F
Federal Register

USA

This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Federal Register
Region
USA
Scope
Regulatory
Published
September 2, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Summary excerpt

The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National I...

Source route

Continue on federalregister.gov

Leave the platform to read the original full article on the publisher site.

Source: Federal Register

Scope: Regulatory

Open original article
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Mifepristone and Analogues To Treat Hypercortisolism-Related Insulin Resistance Disorders | PharmaRadar360